Special Delivery $19.043M Market Capitalization Lexaria Bioscience Corp. (LEXX.Q) is a biotechnology company developing DehydraTECH™, the Company’s proprietary drug delivery technology. In addition to enhancing the speed and efficiency of…
dehydraTECH
Eye Don’t Believe It Fill Disclosure: weekly roundups are intended to provide a quick introduction to various companies. They are not intended to be deep dives or opinion…
Closing the Diabetic Loop Before we get into this week’s sector roundup, let’s talk about diabetes. I am a sucker for sweets, so much so that I was diagnosed…
Old Memories I have always been a sucker for nostalgia. When I first started writing for Equity Guru, I spent most of my time covering biotechnology companies. Whether they…
Lexaria Bioscience (LEXX.Q) announced today that its DehydraTECH™ technology has been embraced by consumer brands and is now available for sale in over 7,000 stores across the US. “Lexaria’s…
Lexaria Bioscience (LEXX.Q) announced today that dosing has been completed for its HYPER-H21-2 study, the Company’s second human clinical study of 2021. Hypertension, also known as high blood…
Lexaria Bioscience (LEXX.Q) today announced results from its antiviral drug molecular characterization study VIRAL-MC21-1 recently completed by Canada’s premier federally funded research organization, the National Research Council (NRC). …
Lexaria Bioscience (LLX.C) announced today that treatment and dosing in its human clinical study, HYPER-H21-1, have been completed ahead of schedule. “Completing this work in the midst of…
Lexaria Bioscience (LXX.C) has received test results for two new DehydraTECH 2.0 cannabidiol (CBD) formulations in its second 2021 applied research and development study program, HYPER-A21-2. “One of our…
Lexaria Bioscience (LXX.C) has provided positive results from its extended stability testing, which has reported unparalleled stability for bottled cannabidiol (CBD)-containing beverages prepared using its technology. “I love reminding…